JPWO2022016198A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022016198A5
JPWO2022016198A5 JP2023502654A JP2023502654A JPWO2022016198A5 JP WO2022016198 A5 JPWO2022016198 A5 JP WO2022016198A5 JP 2023502654 A JP2023502654 A JP 2023502654A JP 2023502654 A JP2023502654 A JP 2023502654A JP WO2022016198 A5 JPWO2022016198 A5 JP WO2022016198A5
Authority
JP
Japan
Prior art keywords
seq
human
monoclonal antibody
amino acid
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023502654A
Other languages
English (en)
Japanese (ja)
Other versions
JP7408008B2 (ja
JP2023535556A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/070898 external-priority patent/WO2022016198A1/en
Publication of JP2023535556A publication Critical patent/JP2023535556A/ja
Publication of JPWO2022016198A5 publication Critical patent/JPWO2022016198A5/ja
Priority to JP2023212722A priority Critical patent/JP7765447B2/ja
Application granted granted Critical
Publication of JP7408008B2 publication Critical patent/JP7408008B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023502654A 2020-07-16 2021-07-16 抗アルファ-4-ベータ-7抗体 Active JP7408008B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023212722A JP7765447B2 (ja) 2020-07-16 2023-12-18 抗アルファ-4-ベータ-7抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052933P 2020-07-16 2020-07-16
US63/052,933 2020-07-16
PCT/US2021/070898 WO2022016198A1 (en) 2020-07-16 2021-07-16 Anti-αlpha-4-βeta-7 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023212722A Division JP7765447B2 (ja) 2020-07-16 2023-12-18 抗アルファ-4-ベータ-7抗体

Publications (3)

Publication Number Publication Date
JP2023535556A JP2023535556A (ja) 2023-08-18
JPWO2022016198A5 true JPWO2022016198A5 (enExample) 2023-11-09
JP7408008B2 JP7408008B2 (ja) 2024-01-04

Family

ID=77338969

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023502654A Active JP7408008B2 (ja) 2020-07-16 2021-07-16 抗アルファ-4-ベータ-7抗体
JP2023212722A Active JP7765447B2 (ja) 2020-07-16 2023-12-18 抗アルファ-4-ベータ-7抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023212722A Active JP7765447B2 (ja) 2020-07-16 2023-12-18 抗アルファ-4-ベータ-7抗体

Country Status (15)

Country Link
US (2) US11639390B2 (enExample)
EP (1) EP4182349A1 (enExample)
JP (2) JP7408008B2 (enExample)
KR (1) KR20230038728A (enExample)
CN (1) CN115867352A (enExample)
AR (1) AR122983A1 (enExample)
AU (1) AU2021307468A1 (enExample)
CA (1) CA3188739A1 (enExample)
CO (1) CO2023001066A2 (enExample)
IL (1) IL299767A (enExample)
MX (1) MX2023000732A (enExample)
TW (1) TWI889871B (enExample)
UY (1) UY39327A (enExample)
WO (1) WO2022016198A1 (enExample)
ZA (1) ZA202300222B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2025038861A1 (en) * 2023-08-15 2025-02-20 Abbvie Inc. Methods of treating human immunodeficiency virus (hiv) disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AP2015008338A0 (en) * 2012-09-26 2015-04-30 Kflp Biotech Llc Compounds for the treatment and prevention of retroviral infections
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Similar Documents

Publication Publication Date Title
JP2020039360A5 (enExample)
JP2024038003A5 (enExample)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2018046872A5 (enExample)
JP2022031635A5 (enExample)
JP2013198490A5 (enExample)
JP2019122405A5 (enExample)
JP2013091655A5 (enExample)
JP2010535205A5 (enExample)
JP2009225799A5 (enExample)
JP2015504421A5 (enExample)
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
IL299221A (en) Cd3 binding antibodies
JP2015163068A5 (enExample)
RU2531523C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2020514277A5 (enExample)
JP2009539348A5 (enExample)
RU2019124709A (ru) КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА
JP2019505477A5 (enExample)
JP2023018678A5 (enExample)
RU2014127287A (ru) Антитела, используемые для пассивной вакцинации против гриппа
RU2018106456A (ru) Антитело к epha4
ATE490983T1 (de) Humane antikörper gegen das humane glycoprotein vi und deren verwendung
RU2013112324A (ru) Моноклональное антитело, имеющее иммуносупрессивную активность, или его антигенсвязывающий фрагмент
JPWO2022016198A5 (enExample)